标题
Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 3, Pages 1735-1748
出版商
American Chemical Society (ACS)
发表日期
2022-01-10
DOI
10.1021/acs.jmedchem.1c01978
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
- (2021) Robert P. Law et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
- (2021) Liqiang Fu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trends in kinase drug discovery: targets, indications and inhibitor design
- (2021) Misty M. Attwood et al. NATURE REVIEWS DRUG DISCOVERY
- IRAK family in inflammatory autoimmune diseases
- (2020) Lin-Chong Su et al. AUTOIMMUNITY REVIEWS
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- (2020) Benjamin J. Solomon et al. Journal of Thoracic Oncology
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
- (2020) Atish Mohanty et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
- (2020) Hongying Gao et al. Protein & Cell
- Targeted protein degradation: current and future challenges
- (2020) Alexander Hanzl et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases
- (2020) Joshua B. Sheetz et al. MOLECULAR CELL
- A small molecule inhibitor of HER3: a proof-of-concept study
- (2020) Audrey Colomba et al. BIOCHEMICAL JOURNAL
- Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase
- (2020) Sébastien L. Degorce et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
- (2020) Bikash Adhikari et al. Nature Chemical Biology
- Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma
- (2020) John M. Hatcher et al. ACS Medicinal Chemistry Letters
- TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
- (2020) Emiliano Cocco et al. Cancer Discovery
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
- (2020) Chunjian Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prospects for pharmacological targeting of pseudokinases
- (2019) Jennifer E. Kung et al. NATURE REVIEWS DRUG DISCOVERY
- Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
- (2019) Johannes Popow et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2019) Owen A. O’Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
- (2019) Jin Zhou et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)
- (2019) Ryan Moslin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Neutrophils deficient in innate suppressor IRAK-M enhances anti-tumor immune responses
- (2019) Yao Zhang et al. MOLECULAR THERAPY
- Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR
- (2019) Carlos Alvarado et al. MOLECULES
- Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK–Paxillin Interaction
- (2019) Timothy Marlowe et al. SLAS Discovery
- Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
- (2019) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
- (2018) Xiaoyun Lu et al. MEDICINAL RESEARCH REVIEWS
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions
- (2018) Antoine Mousson et al. Cancers
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- KSR as a therapeutic target for Ras-dependent cancers
- (2017) Beth K. Neilsen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)
- (2017) Fatima Ardito et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
- (2017) Shaomeng Wang et al. Cold Spring Harbor Perspectives in Medicine
- FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes
- (2016) B. E. Kessler et al. MOLECULAR CANCER RESEARCH
- Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
- (2016) Neil S. Dhawan et al. NATURE
- A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer
- (2016) Daniel Dauch et al. NATURE MEDICINE
- Structural Basis for the Non-catalytic Functions of Protein Kinases
- (2016) Jennifer E. Kung et al. STRUCTURE
- Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype
- (2016) Feimeng Zheng et al. Nature Communications
- Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
- (2015) Priscilla N. Kelly et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Conformation-Selective ATP-Competitive Inhibitors Control Regulatory Interactions and Noncatalytic Functions of Mitogen-Activated Protein Kinases
- (2014) Sanjay B. Hari et al. CHEMISTRY & BIOLOGY
- Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK–VEGFR3 protein–protein interaction
- (2014) Priyanka N. Gogate et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacological targeting of the pseudokinase Her3
- (2014) Ting Xie et al. Nature Chemical Biology
- Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
- (2014) Neroshan Thevakumaran et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
- (2014) P. J. Lupardus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
- (2014) P. Littlefield et al. Science Signaling
- Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
- (2013) Deniz A. Ucar et al. Anti-Cancer Agents in Medicinal Chemistry
- A Small-molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK and Mdm-2 Interaction, and Blocks Breast and Colon Tumorigenesis in vivo
- (2013) Vita M. Golubovskaya et al. Anti-Cancer Agents in Medicinal Chemistry
- Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth
- (2013) Vita M Golubovskaya et al. BMC CANCER
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- The secret life of kinases: functions beyond catalysis
- (2011) Jens Rauch et al. Cell Communication and Signaling
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
- (2011) Kathleen Aertgeerts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A kinase-independent role for Aurora A in the assembly of mitotic spindle microtubules in Caenorhabditis elegans embryos
- (2011) Mika Toya et al. NATURE CELL BIOLOGY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
- (2010) M. D. Schaller JOURNAL OF CELL SCIENCE
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Why do Kinase Inhibitors Cause Cardiotoxicity and What can be Done About It?
- (2010) Hui Cheng et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling
- (2009) Shaohui Hu et al. CELL
- Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo
- (2009) Elena V. Kurenova et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
- (2009) Monica Red Brewer et al. MOLECULAR CELL
- Evolution of domain combinations in protein kinases and its implications for functional diversity
- (2009) Krupa Deshmukh et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation
- (2008) Ssang-Taek Lim et al. MOLECULAR CELL
- Focal Adhesion Kinase Versus p53: Apoptosis or Survival?
- (2008) W. G. Cance et al. Science Signaling
- Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase
- (2008) Chen Qiu et al. STRUCTURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More